Novartis announces an expansion of its community health programs to reach heart disease and cancer patients in hard-to-reach communities across more than 30 countries by 2030. The footprint will nearly triple from 11 to over 30 countries, including five U.S. cities under Inclusive Health Accelerators to improve cancer screening and referrals, plus Community Health Initiatives expanding diagnosis and treatment in low- and middle-income countries. CARDIO4Cities, developed by the Novartis Foundation, will scale to 23 countries by 2030 to leverage real-time data, AI, and partnerships for prevention and management of cardiometabolic diseases. In the U.S., IHAs will begin in New York, Los Angeles, Detroit, Houston, and Baltimore, building on HEART program collaboration with Meharry Medical College. CHIs currently operate in Vietnam, Rwanda, and Bolivia, with expansion planned in at least seven more countries by 2030. CARDIO4Cities already operates in eight countries (Brazil, U.S., Belgium, Portugal, Finland, Brunei, Singapore, Australia) with aims to reach 30 major cities by 2030. In Vietnam, an 18-month pilot linked 400,000 people to screening and treatment and substantially increased control rates for high blood pressure and diabetes, according to Final Report for the Cung Song Khoe Program 2024-2025 by the Health Strategy and Policy Institute, Ministry of Health. The company notes forward-looking statements and risks typical of pharmaceutical communications and underscores ongoing collaborations with governments and health authorities, including the Government of Vietnam. The release cites substantial programmatic gains in hypertension and diabetes control and emphasizes the potential for scalable solutions to improve access to care worldwide.
← Atlas › News › Health & Lifestyle